The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications
Open accessAbstract
The accepted view of ovarian carcinogenesis is that carcinoma begins in the ovary, undergoes progressive "dedifferentiation" from a well to a poorly differentiated tumor, and then spreads to the pelvic and abdominal cavities before metastasizing to distant sites. It has therefore been reasoned that survival for this highly lethal disease could be improved by developing screening methods that detect disease when it is confined to the ovary. To date, however, no prospective randomized trial of any ovarian cancer screening test(s) has demonstrated a decrease in mortality. We believe that one of the main reasons for this is that the dogma underlying ovarian carcinogenesis is flawed. Based on studies performed in our laboratory during the last decade, we have proposed a model of ovarian carcinogenesis that takes into account the diverse nature of ovarian cancer and correlates the clinical, pathological, and molecular features of the disease. In this model, ovarian tumors are divided into 2 groups designated type I and type II. Type I tumors are slow growing, generally confined to the ovary at diagnosis, and develop from well-established precursor lesions that are termed "borderline" tumors. Type I tumors include low-grade micropapillary serous carcinoma, mucinous, endometrioid, and clear cell carcinomas. They are genetically stable and are characterized by mutations in a number of different genes including KRAS, BRAF, PTEN, and beta-catenin. Type II tumors are rapidly growing highly aggressive neoplasms for which well-defined precursor lesions have not been described. Type II tumors include high-grade serous carcinoma, malignant mixed mesodermal tumors (carcinosarcomas), and undifferentiated carcinomas. This group of tumors has a high level of genetic instability and is characterized by mutation of TP53. The model helps to explain why current screening techniques, aimed at detecting stage I disease, have not been effective. Tumors that remain confined to the ovary for a long period belong to the type I group, but they account for only 25% of the malignant tumors. Most of what is considered ovarian cancer belongs to the type II category, and these are only rarely confined to the ovary. Although the reasons for this are not entirely clear, possible explanations include rapid spread from the ovary early in carcinogenesis and development of carcinoma in extra ovarian sites, notably, the peritoneum and fallopian tube, with secondary involvement of the ovary. The latter tumors are advanced stage at their inception. Therefore, a more realistic end point for the early detection of ovarian cancer is volume and not stage of disease. The model does not replace the histopathologic classification but, by drawing attention to the molecular genetic events that play a role in tumor progression, sheds light on new approaches to early detection and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationKindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationRonnett, B. M., Zahn, C. M., Kurman, R. J., Kass, M. E., Sugarbaker, P. H., & Shmookler, B. M. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199512000-00006 · Cited by 776
Self-citationTumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament
Scully, R. E., Young, R. H., & Clement, P. B. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199907000-00019 · Cited by 617
Dinulescu, D. M., Ince, T. A., Quade, B. J., Shafer, S. A., Crowley, D., & Jacks, T. (2005) · Nature Medicine · doi:10.1038/nm1173 · Cited by 604
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M., Kindelberger, D. W., & Lee, Y. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011a21f · Cited by 512
Sato, N., Tsunoda, H., Nishida, M., Morishita, Y., Takimoto, Y., Kubo, T., & Noguchi, M. (2000) · PubMed · doi:10.11501/3187985 · Cited by 448
Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
OBATA, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix‐Trench, G., Thomas, E. J., & Campbell, I. (1998) · PubMed · Cited by 429
Seidman, J. D., & Kurman, R. J. (2000) · Human Pathology · doi:10.1053/hp.2000.8048 · Cited by 410
Self-citationSinger, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Self-citationPrecursor lesions of ovarian epithelial malignancy
Feeley, K. M., & Wells, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01042.x · Cited by 351
Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma
Singer, G., Kurman, R. J., Chang, H.-W., Cho, S. K. R., & Shih, I.-M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62549-7 · Cited by 340
Self-citationBurks, R. T., Sherman, M. E., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00003 · Cited by 314
Self-citationWu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Seidman, J. D., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00004 · Cited by 290
Self-citationp53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R., Merritt, V, Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Milner, J., Medcalf, E. A., & Cook, A. C. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.1.12 · Cited by 243
Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
Mok, S. C., Bell, D. A., KNAPP, R. C., Fishbaugh, P. M., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Tsao, S. (1993) · PubMed · Cited by 237
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello, M. G., Ebina, M., Linnoila, R. I., Henry, M., Nash, J. D., Park, R. C., & Birrer, M. J. (1993) · PubMed · Cited by 211
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
Self-citationEnomoto, T., Weghorst, C. M., Inoue, M., Tanizawa, O., & Rice, J. M. (1991) · PubMed Central · Cited by 192
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Self-citationSpectrum of Mutation and Frequency of Allelic Deletion of the p53 Gene in Ovarian Cancer
Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R. C., & Berchuck, A. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.18.1513 · Cited by 184
Kounelis, S., Jones, M. W., Papadaki, H., Bakker, A., Swalsky, P., & Finkelstein, S. D. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90394-x · Cited by 184
Plante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1859::aid-cncr2820730714>3.0.co;2-l · Cited by 177
Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers
Chan, W.-Y., Cheung, K.-K., Schorge, J. O., Huang, L.-W., Welch, W. R., Bell, D. A., Berkowitz, R. S., & Mok, S. C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64744-x · Cited by 171
Dehari, R., Kurman, R. J., Logani, S., & Shih, I. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31802cbbe9 · Cited by 168
Self-citationHeritability and molecular genetic studies of endometriosis
Bischoff, F. Z. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.1.37 · Cited by 166
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer
Prowse, A. H., Manek, S., Varma, R., Liu, J., Godwin, A. K., Maher, E. R., Tomlinson, I. P. M., & Kennedy, S. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.21845 · Cited by 164
Schuijer, M., & Berns, E. M. J. J. (2003) · Human Mutation · doi:10.1002/humu.10181 · Cited by 160
Ichikawa, Y., Nishida, M., Suzuki, H., Yoshida, S., Tsunoda, H., Kubo, T., Uchida, K., & Miwa, M. (1994) · PubMed · Cited by 144
p53 Mutations and Expression in Ovarian Cancers: Correlation with Overall Survival
Wen, W., Reles, A., Runnebaum, I. B., Sullivan‐Halley, J., Bernstein, L., Jones, L. A., Felix, J. C., Kreienberg, R., El‐Naggar, A. K., & Press, M. F. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199901000-00005 · Cited by 143
Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
Self-citationMicrosatellite instability and alterations in the HMSH2 gene in human ovarian cancer
Fujita, M., Enomoto, T., Yoshino, K., Nomura, T., Buzard, G. S., Inoue, M., & Okudaira, Y. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640602 · Cited by 125
Salani, R., Kurman, R. J., Giuntoli, R. L., Gardner, G. J., Bristow, R. E., Wang, T., & Shih, I. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01039.x · Cited by 120
Self-citationCaduff, R. F., Svoboda-Newman, S. M., Ferguson, A. W., Johnston, C. M., & Frank, T. S. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199903000-00012 · Cited by 102
Molecular Genetic Defects in Endometriosis
Thomas, E. J., & Campbell, I. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000052878 · Cited by 102
Okuda, T., Otsuka, J., Sekizawa, A., Saito, H., Makino, R., Kushima, M., Farina, A., Kuwano, Y., & Okai, T. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00149-x · Cited by 95
Allelic imbalance and mutations of the PTEN gene in ovarian cancer
Saito, M., Okamoto, A., Kohno, T., Takakura, S., Shinozaki, H., Isonishi, S., Yasuhara, T., Yoshimura, T., Ohtake, Y., Ochiai, K., et al. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2<160::aid-ijc2>3.0.co;2-5 · Cited by 95
Human ovarian cancer of the surface epithelium
Berchuck, A., & Carney, M. E. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00061-0 · Cited by 94
Common Genetic Changes between Endometriosis and Ovarian Cancer
小畑, 孝., & Hoshiai, H. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000052877 · Cited by 93
The genetic analysis of ovarian cancer
Shelling, A. N., Cooke, I. E., & Ganesan, T. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.367 · Cited by 92
Shvartsman, H. S., Sun, C. C., Bodurka, D. C., Mahajan, V., Crispens, M. A., Lu, K. H., Deavers, M. T., Malpica, A. L., Silva, E. G., & Gershenson, D. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.030 · Cited by 73
Cuatrecasas, M., Erill, N., Musulén, E., et al. (1998) · PubMed · Cited by 72
Ortiz, B. H., Ailawadi, M., Colitti, C., Muto, M. G., Deavers, M. T., Silva, E. G., Berkowitz, R. S., Mok, S. C., & Gershenson, D. M. (2001) · PubMed · Cited by 68
Yang, D., Smith, E. R., Cohen, C., Wu, H., Patriotis, C., Godwin, A. K., Hamilton, T. C., & Xu, X. (2002) · Cancer · doi:10.1002/cncr.10497 · Cited by 67
Early Recurrence of Ovarian Serous Borderline Tumor as High-grade Carcinoma: A Report of Two Cases
Parker, R. L., Clement, P. B., Chercover, D. J., Sornarajah, T., & Gilks, C. B. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000130049.19643.f6 · Cited by 57
Staebler, A., Heselmeyer‐Haddad, K., Bell, K. A., Riopel, M. A., Perlman, E. J., Ried, T., & Kurman, R. J. (2002) · Human Pathology · doi:10.1053/hupa.2002.30212 · Cited by 52
Self-citationExpression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma
Mao, T., Hsu, C., Yen, M. J., Gilks, C. B., Sheu, J. J., Gabrielson, E. W., VANG, R. S., Cope, L., Kurman, R. J., Wang, T., et al. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.04.008 · Cited by 44
Self-citationGallardo, A., Matías‐Guiu, X., Lagarda, H., Catasús, L., Bussaglia, E., Gras, E., Suarez, D., & Prat, J. (2002) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200207000-00010 · Cited by 42
Expression of ?-glutamyl cysteine synthetase in nonsmall cell lung carcinoma
Soini, Y., T�rm�nen-N�p�nkangas, U., J�rvinen, K., Kaarteenaho–Wiik, R., P��kk�, P., & Kinnula, V. L. (2001) · Cancer · doi:10.1002/1097-0142(20011201)92:11<2829::aid-cncr10094>3.0.co;2-3 · Cited by 40
Kareem, B. N., Karlsen, F., Holm, R., Hennig, E. M., Suo, Z., Emilsen, E., Hellesylt, E., & Nesland, J. M. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199712)183:4<424::aid-path949>3.0.co;2-l · Cited by 4
Cited by
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Self-citation
Metadata
- Authors
- Kurman, R. J., & Shih, I.-M.
- Venue
- International Journal of Gynecological Pathology
- Published
- 2008-02
- Volume
- PAP
- Issue
- 2
- Pages
- 151-60
- ISSN
- 0277-1691 (ISSN-L)
- OpenAlex
- W1994563300
- Cited by
- 460
- References
- 59
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.